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INT ROD UCT ION
Primary myelofibrosis (PMF) is a myeloproliferative neo-
plasm characterized by increased BM cellularity, increased 
numbers of atypical megakaryocytes, decreased erythropoie-
sis, and extramedullary hematopoiesis (International Agency 
for Research on Cancer and World Health Organization, 
2008). A defining feature of PMF is progressive BM fibrosis, 
and higher-grade BM fibrosis is associated with poor progno-
sis (Thiele and Kvasnicka, 2006; Vener et al., 2008). Although 
constitutive activation of the JAK–STAT pathway plays a 
key role in the disease pathogenesis (Rampal et al., 2014), 
treatment of patients with JAK inhibitors such as ruxolitinib 
usually does not reverse BM fibrosis or eradicate the disease 
(Harrison et al., 2012; Verstovsek et al., 2012). Therefore, tar-
geting genes or pathways involved in the induction of fibrosis 
in PMF may be necessary to significantly modify the disease 
course. However, the mechanism of and the primary cell re-
sponsible for BM fibrosis in PMF remain unclear. Because 
mesenchymal stromal cells (MSCs) produce collagen and 
fibronectin and cultured PMF BM MSCs do not originate 
from the neoplastic clone (Jacobson et al., 1978; Nowell and 
Finan, 1978; Castro-Malaspina et al., 1982; Greenberg et al., 
1987; Wang et al., 1992), BM fibrosis in PMF is thought to 
be reactive, caused indirectly by an overproduction of growth 
factors by clonal megakaryocytes or platelets that stimulate 
MSCs to induce BM fibrosis (Groopman, 1980).
However, in other diseases with evolving tissue fibrosis, 
such as pulmonary fibrosis (Mehrad and Strieter, 2012), end-
stage liver or kidney disease (Kisseleva et al., 2006; Reich et 
al., 2013), heart disease (Keeley et al., 2011), and autoimmune 
disorders (Reilkoff et al., 2011), fibrocytes, spindle-shaped 
fibroblast-like cells that differentiate from a subpopulation 
of CD14+ monocytes (Bucala et al., 1994; Abe et al., 2001; 
Yang et al., 2002; Pilling et al., 2003; Reilkoff et al., 2011), are 
associated with the induction of fibrosis. Fibrocytes express 
markers of both hematopoietic cells (CD34, CD43, CD45, 
CD68, LSP-1, and major histocompatibility complex class 
II) and stromal cells (collagen I, collagen III, and fibronec-
tin; Bucala et al., 1994; Abe et al., 2001; Pilling et al., 2009). 
They also express a variety of chemokine receptors, secrete 
growth factors and cytokines, regulate tissue repair (Bucala 
et al., 1994; Reilkoff et al., 2011), and are thought to consti-
tute a subset of myeloid-derived suppressor cells (Zhang et al., 
2013). Although they make up <1% of BM cells, fibrocytes 
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and/or their precursors migrate through the blood to the site 
of organ damage and participate in induction of fibrosis in 
the skin, lung, kidney, liver, and heart (Reilkoff et al., 2011). 
Notably, the differentiation of monocytes into fibrocytes is 
inhibited by the pentraxin protein serum amyloid P (SAP) 
component (pentraxin-2), a 125-kD protein produced by the 
liver (Steel and Whitehead, 1994; Hutchinson et al., 2000), 
repeated injections of which have been shown to ameliorate 
fibrosis in multiple organ systems (Haudek et al., 2006, 2008; 
Pilling et al., 2007; Castaño et al., 2009; Reilkoff et al., 2011).
Because PMF is characterized by increased myeloid 
proliferation and monocyte-derived fibrocytes have been as-
sociated with fibrosis in various organs, we hypothesized that 
clonal neoplastic fibrocytes play a role in the induction of 
BM fibrosis in PMF. In this study, we show that the BM of 
PMF patients harbors more neoplastic functionally distinct 
fibrocytes and fewer MSCs than hematologically normal BM. 
In addition, we detected an overabundance of fibrocytes in 
the BM and spleen of an established PMF mouse model and 
a xenograft mouse model of PMF created using BM-derived 
low-density cells from patients with PMF. Treatment of PMF 
xenograft mice with recombinant human SAP (PRM-151) 
significantly extended survival and slowed BM fibrosis.
RES ULTS
Neoplastic fibrocytes are overrepresented in the BM  
of patients with PMF and are functionally distinct
To determine whether neoplastic fibrocytes are present in the 
BM of patients with PMF, we analyzed BM biopsy specimens 
by immunofluorescence. In PMF BM, we detected very few 
cells staining positive for CD90 (usually detected in MSCs) 
and an abundance of cells costaining positive for CD45/
CD68 and CD45/procollagen I, markers that are indicative of 
fibrocytes, but not CD45/PM-2K, a marker of macrophages 
(Fig. 1 A, top; Pilling et al., 2009). In contrast, hematologically 
normal BM contained very few cells coexpressing CD45/
procollagen I or CD45/CD68, indicating that unlike macro-
phages and MSCs, fibrocytes were either not present or there 
were too few to be detected (Fig. 1 A, bottom). Quantitation 
by multispectral imaging showed significantly more CD45+/
CD68+ and CD45+/procollagen I+ cells and significantly 
fewer CD45+/PM-2K+ cells (macrophages) and CD90+/
CD45− (MSCs) in PMF than normal BM (Fig.  1  B). The 
CD45+/CD68+ cells had a 20q deletion as the original BM 
cytogenetic abnormality (Fig. 1 C). Cultured fibrocytes and 
MSCs from PMF and normal BM had an immunophenotype 
similar to that of biopsy samples (Fig. 2 A). Morphologically, 
cultured fibrocytes from PMF BM were characterized by 
thicker, more convoluted cytoplasmic extensions and more 
intense staining for type III collagen than those from normal 
BM, whereas MSCs from normal and PMF BM were not 
different (Fig. 2, B and C).
Fluorescence in situ hybridization (FISH) analysis of BM 
smears from a PMF patient with a 20q deletion showed cells 
with the 20q deletion coexpressing CD45/CD68 (Fig. 1 C) 
and CD45 and collagen III (Fig. 3 A), suggesting that these 
neoplastic cells are fibrocytes. To confirm that PMF fibrocytes 
originate from the neoplastic clone, quantitative allele-specific 
PCR was used. The JAK2-V617F mutation was detected in 
cultured fibrocytes, low-density BM cells, granulocytes, and 
CD14+ and CD14− leukocytes but not MSCs from 12 patients 
with JAK2-V617F–postive PMF (Fig. 3 B). Similarly, CALR 
mutations were detected in low-density BM cells, CD14+ cells, 
and fibrocytes but not MSCs from seven patients with a CALR 
mutation (Fig. 3 C). Additionally, cultured fibrocytes from four 
patients also harbored the chromosomal abnormalities detected 
in the original BM aspirates (trisomy 1 and the 20q deletion), 
whereas MSCs did not (Fig. 3 D). Collectively, these data show 
that BM from PMF patients contains an overabundance of 
hematopoietic lineage–derived cells that produce procollagen I 
and fewer MSCs and macrophages than normal BM, and PMF 
BM–derived fibrocytes originate from the neoplastic clone.
To determine whether PMF fibrocytes were functionally 
different from normal fibrocytes, we studied the fibrocytes’ 
function. We found that PMF fibrocytes stimulated hemato-
poietic colony proliferation significantly more than normal 
fibrocytes (Fig. 4 A), and this effect required cell to cell contact. 
PMF and normal fibrocytes also showed differential expression 
of genes known to be deregulated in PMF (Fig. 4 B), and PMF 
fibrocytes secreted significantly higher levels of inflammatory 
cytokines/chemokines (Fig. 4 C). Levels of secreted TGF-β 
from PMF fibrocytes were not different from those of normal 
fibrocytes (Fig. 4 D). Collectively, these data suggest that PMF 
fibrocytes are functionally different from normal fibrocytes.
SAP (PRM-151) but not ruxolitinib inhibits PMF and normal 
BM–derived fibrocytes in vitro
Because our data suggested that fibrocytes play a role in the 
induction of BM fibrosis in PMF, we looked for a means of 
inhibiting fibrocyte differentiation. Because levels of SAP, an 
inhibitor of fibrocyte differentiation, are reduced in patients 
with fibrotic diseases likely because of increased consumption 
(Castaño et al., 2009; Murray et al., 2011), we measured SAP 
in plasma samples from 39 patients with PMF and nine healthy 
age-matched individuals. Plasma SAP levels were significantly 
lower in PMF patients than in normal donors (Fig. 5 A). In 
contrast, levels of C-reactive protein (CRP) were higher in 
PMF patients than in normal donors (Fig. 5 B). Albumin lev-
els were the same in both groups (Fig. 5 C).
In culture, PMF BM–derived fibrocyte differentiation 
was significantly inhibited by SAP (PRM-151) in a dose-de-
pendent manner. However, PMF fibrocytes were less sensi-
tive to SAP than were normal BM–derived fibrocytes (Fig. 5, 
D and E). In contrast, the JAK2 inhibitor ruxolitinib had no 
significant effect on fibrocyte differentiation (Fig. 5 F).
Fibrocytes are expanded in BM and 
spleen of MPL-W515L mice
To determine whether, like in human PMF BM, fibrocytes 
are increased in a PMF mouse model, we analyzed BM and 
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spleen sections from MPL-W515L mice that develop a PMF-
like phenotype (Pikman et al., 2006). 2 wk after induction 
of MPL-W515L, large numbers of immature myeloid cells 
and dense megakaryocyte clusters with aberrant nuclear/
cytoplasmic ratios and hyperchromatic and irregular nuclei 
were found in the BM and spleen (Fig.  6  A). In addition, 
a large number of cells coexpressing CD11b/procollagen I, 
CD45/procollagen I, and CD68/procollagen I were found 
in both the BM and spleen of MPL-W515L mice but not 
age-matched MPL-WT mice (Fig. 6, B–D). We then treated 
MPL-W515L mice with SAP (PRM-151) immediately 
after induction. Mice were initially given nine daily injec-
tions of 10 mg/kg SAP (PRM-151) and then twice weekly 
thereafter. Both placebo- and SAP (PRM-151)-treated 
Figure 1. Detection of neoplastic fibrocytes in PMF BM biopsy specimens. (A) Immunofluorescent staining of BM biopsy sections from three PMF 
patients (top) or three normal controls (bottom). Staining for CD45 and CD68 was used to discriminate monocyte-derived cells (CD45+/CD68+) from 
CD68-positive MSCs. CD45 and procollagen I (Procol-I) were used to detect fibrocytes. CD90 was used to detect MSCs that do not express CD45, and CD45 
and PM-2K were used to detect tissue macrophages. Images are representative of three patients. Bars, 50 µm. (B) Quantitation of immunostained cells on 
BM slides. Images of random HPFs were analyzed using an automated multispectral imaging microscope. Box and whisker plots of CD45+, CD68+, CD90+, 
PM-2K+, procollagen I+, and dual-labeled cells (Merge) are depicted. The number of CD90+/CD45− cells is the inverse of the merged data shown in the top 
right plot. The data shown are from BM and spleen samples from three patients (four slides/patient were analyzed). Boxes show the median and interquartile 
range, and whiskers denote the minimum and maximum data points. *, P < 0.05; **, P < 0.01 (Student’s t test with Welch’s correction comparing normal and 
PMF [merge]). (C) FISH images of a BM biopsy from the same patient showing CD45+/CD68+ cells (yellow) lacking one long arm of chromosome 20 (20q−; 
cells showing only one red dot). Staining for chromosome 1 was used as an internal control (two green dots). Another field from the same BM specimen, 
depicting 20q− cells, is shown at the bottom. Bars: (left) 50 µm; (right) 2.5 µm.
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Figure 2. Morphology of PMF and normal 
BM–derived fibrocytes. (A) Immunofluo-
rescence staining of PMF BM–derived fibro-
cytes and MSCs. (a) Costaining for CD45 and 
CD68. Fibrocytes were stained both by CD45 
and CD68 antibodies (shown in light yellow), 
whereas MSCs were not stained by anti-CD45 
antibodies. (b) Costaining for CD45 and PM-
2K. Fibrocytes were stained by anti-CD45 but 
not by anti–PM-2K antibodies, whereas MSCs 
had no detectable staining for CD45 or PM-2K. 
(c) Staining for CD45 in fibrocytes and CD90 in 
MSCs. (d) Staining for both CXCR4 and colla-
gen III (Col-III) is evident in both fibrocytes and 
MSCs. (e) Strong staining for collagen I in MSCs 
and weak staining in fibrocytes. (f) Staining for 
both CD34 and reticulin in fibrocytes but only 
reticulin in MSCs. (g) Staining for fibronectin 
in both fibrocytes and MSCs. (h–j) Staining for 
osteonectin, CD44, and actin in both fibrocytes 
and MSCs. Bars, 10 μm. DAPI staining is shown 
in blue. (B) Representative images of fibrocytes 
and MSCs grown from low-density BM cells of 
patients with PMF and hematologically normal 
donors. Images taken at day 7, 14, and 21 are 
depicted. Normal and PMF BM–derived fibro-
cytes are morphologically distinct from MSCs. 
Compared with normal BM–derived fibrocytes, 
PMF BM–derived fibrocytes are thicker, and 
their cytoplasmic extensions are more convo-
luted. Bar, 250 µm. (C) Silver staining in normal 
BM– and PMF-derived fibrocytes from two 
different patients showing that PMF BM–de-
rived fibrocytes exhibit darker and thicker sil-
ver-stained cytoplasm, suggesting that they 
produce high levels of reticulin and/or type 
III collagen. Bar, 250 µm.
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mice died within 2 wk. However, BM and spleen specimens 
from SAP (PRM-151)-treated mice had much less fibrosis 
and significantly fewer fibrocytes than those from untreated 
mice (Fig. 6, E and F).
Engraftment of PMF BM cells in NOD-SCIDγ (NSG) mice
To determine whether BM fibrosis is induced by human fi-
brocytes, we generated a xenograft mouse model. In a series 
of similar experiments, we injected NSG mice with sin-
gle-donor PMF or normal BM low-density cells. The PMF 
BM cells were obtained from seven patients with the JAK2-
V617F mutation and cytogenetic abnormalities such as a 20q 
deletion, which could be interrogated by FISH. Engraft-
ment of human BM–derived cells was confirmed by flow 
cytometry. All mice injected with human BM cells showed 
engraftment and had approximately the same percentage of 
HLA-ABC+ cells throughout their life (Fig. 7 A and Table 
S4). Karyotype and FISH analyses performed after the mice 
became sick and were euthanized confirmed the presence of 
mouse and human chromosomes in mice injected with PMF 
BM (Fig. 7, B and C). The human chromosomes harbored 
the 20q deletion present in the BM PMF cells that were in-
jected into mice. Rare (≤1%) cells with two copies of human 
chromosome 20 were also detected by FISH, suggesting that 
in addition to the PMF BM cells, donor-derived normal he-
matopoietic cells engrafted as well.
3 mo after injection of normal or PMF BM cells, two 
randomly selected mice from each cohort were euthanized. 
Mice injected with PMF BM low-density cells had enlarged 
spleens, whereas mice injected with normal BM had spleens 
that were similar in size to those of the IMDM-injected 
(control) mice (Fig. 7 D). BM sections from mice injected 
with PMF low-density cells were hypercellular with a high 
myeloid/erythroid (M:E) ratio and an increased number of 
Figure 3. PMF BM–derived fibrocytes originate from the neoplastic clone and are functionally distinct from normal fibrocytes. (A) FISH images 
of a BM smear showing coexpression of CD45/collagen III in cells with the 20q deletion. (B) Median percentage of JAK2 T allele in BM-derived cells from 12 
PMF patients who tested positive for the JAK2 mutation and seven BM and five PB samples from normal individuals (control). Boxes show the median, and 
interquartile range and whiskers denote the minimum and maximum data points. (C) Fragment analysis of the CALR gene showing the presence of a 52-bp 
deletion (peak at 210 bp) in BM mononuclear cells, CD14+ cells, and fibrocytes but not MSCs from seven PMF patients known to harbor a CALR deletion. 
Representative data from two patients are shown. (D) Representative FISH images of MSCs and fibrocytes cultured from low-density BM cells from two 
patients with PMF who had either trisomy 1q (top left) or a 20q deletion (top right). FISH analysis was performed using 20q, 1q, and 1p probes.
Fibrocytes induce bone marrow fibrosis in PMF | Verstovsek et al.6
immature myeloid cells, blasts, and reticulin fibrosis. Their 
splenic architecture was markedly altered, and the spleens 
were infiltrated with left-shifted myeloid cells with increased 
blasts, a large number of immature atypical megakaryocytes, 
and marked reticulin fibrosis (Fig.  7  E, right). The BM of 
mice injected with normal BM cells were normocellular with 
a normal M:E ratio and morphologically normal megakaryo-
cytes with no fibrosis. Their splenic architecture was preserved, 
with morphologically normal lymphocytes, a small number 
of myeloid cells, and a few megakaryocytes (Fig. 7 E, left).
Immunofluorescence analysis showed an overabun-
dance of cells coexpressing CD68/CD45 and procollagen I/
Figure 4. Characterization of PMF and normal fibrocytes. (A) The effect of normal- and PMF-derived adherent fibrocytes on hematopoietic colo-
ny-forming proliferation. Data shown are the number of burst units or CFUs as a percentage of the number of CFUs in the absence of a fibrocyte underlayer 
(control). The figure depicts data derived from experiments performed using fibrocyte underlayers derived from 12 normal and 22 PMF BM samples and an 
additional 6 normal (Norm) and 11 PMF BM samples to test colony formation. Each sample was tested in duplicate. The mean number of colonies in control 
normal BMs were: BFU-E, 2; CFU-GM, 83; and CFU megakaryocyte (CFU-MK), 9.2. Control PMF BM colonies were: BFU-E, 94; CFU-GM, 197; and CFU mega-
karyocyte, 30. Boxes show the median and interquartile range, and whiskers denote the minimum and maximum data points. Statistical differences were 
measured by one-way analysis of variance using Sidak’s multiple comparisons test with an α of 0.05. **, P < 0.01; ****, P < 0.0001. (B) Heat map showing 
gene expression in PMF and normal fibrocytes. A colored gradient from blue (low expression) to yellow (high expression) is shown. Gene expression was 
measured in 24 PMF and 9 normal control samples. PMF fibrocytes have an increased expression of JAK2, EZH2, and LNK, which is likely associated with 
the JAK2V617F mutation. PMF fibrocytes also expressed higher levels of CD44, a cell surface glycoprotein involved in cell–cell interactions, cell adhesion, and 
cell migration (Maharjan et al., 2011), and lower levels of IHH, which has been shown to result in intestinal inflammation and fibrosis (van Dop et al., 2010). 
(C) Heat maps comparing levels of cytokines/chemokines secreted by PMF and normal fibrocytes. A colored gradient from blue (low levels) to yellow (high 
levels) is shown. 11 PMF and 6 normal samples were used. PMF fibrocytes secreted significantly higher levels of inflammatory cytokines (IL-6 and TNF) and 
chemokines (CCL15 and osteopontin) than normal fibrocytes. Differential expression was analyzed by Student’s t test. *, P < 0.05; **, P < 0.01. (D) Levels of 
TGF-β1 and TGF-β2 secreted from cultured fibrocytes derived from BM from 17 PMF patients and 10 normal controls. Data are the mean of two measure-
ments. Cytokine levels were measured by an enzyme-linked immunosorbent assay.
7JEM
CD45 in the BM and to a lesser extent the spleens of mice 
injected with PMF BM cells (Fig. 8 A) but not those injected 
with normal BM cells (Fig. 8 B). Although macrophages also 
coexpress CD45/CD68, they could be distinguished from 
fibrocytes by their size and morphology. In addition, the num-
ber of CD68+/CD45+ and procollagen I+/CD45+ cells per 
square millimeter in engrafted BM (Fig. 8 C, top) and spleens 
(Fig. 8 C, bottom) was significantly higher in mice injected 
with PMF cells than in those injected with normal BM cells. 
11% of the BM low-density cells harvested from mice injected 
with PMF BM cells coexpressed CD68+/CD45+ as assessed by 
flow cytometry (Fig. 8 D), and fibrocytes cultured from these 
cells carried the 20q-cytogenetic abnormality present in the 
injected BM cells from the patient, implying that these fibro-
cytes originated from the human neoplastic clone (Fig. 8 E).
SAP (PRM-151) extends survival of xenograft mice
Because SAP (PRM-151) inhibited PMF fibrocyte differ-
entiation in culture (Fig.  5  D), we investigated whether it 
would inhibit the development of BM fibrosis in our xe-
nograft mouse model. As a pilot experiment, 20 NSG mice 
transplanted with BM low-density cells from a PMF patient 
were injected intraperitoneally with 10 mg/kg SAP (PRM-
151) or the drug’s vehicle (placebo) starting the day after BM 
transplantation according to the treatment schedule shown in 
Fig. 9 A. By day 241, all 10 placebo-treated NSG mice had 
died, whereas all 10 mice in the SAP (PRM-151)–treated 
group were still alive and healthy (Fig. 9 B).
To determine whether SAP could slow or reverse BM 
fibrosis, an additional 30 NSG mice were transplanted with 
low-density cells from another PMF patient harboring the 
JAK2V617F mutation and a 20q deletion. The mice were ran-
domized into three treatment groups as follows: (group A) 
10 mice were injected intraperitoneally with 10 mg/kg SAP 
(PRM-151) as described in the previous paragraph starting 
2 wk after transplantation; (group B) 10 mice received SAP 
(PRM-151) starting 2 mo after transplantation; and (group 
C, placebo) 10 mice were injected intraperitoneally with the 
Figure 5. Plasma levels of SAP, CRP, and albumin in PMF patients and effect of SAP and ruxolitinib on PMF and normal BM–derived fibrocytes. 
(A–F) Levels of SAP (A), CRP (B), and albumin (C) in plasma samples from 39 patients with PMF and nine age-matched healthy individuals (control). (A) Data 
are mean ± SD. SAP levels in PMF (12.6 ± 5.39 µg/ml) and normal (21.4 ± 3.92 µg/ml) plasma samples (P < 0.0006) are shown. (B) Data are mean ± SD. CRP 
levels in PMF (13.38 ± 10.96 µg/ml) and normal (4.42 ± 1.96 µg/ml) plasma samples (P = 0.019) are shown. (C) Mean ± SD albumin levels in PMF (39.76 ± 
4.55 mg/ml) and normal (40.5 ± 3.43 mg/ml) plasma samples (P = 0.6) are shown. Clinical characteristics of the 39 patients are shown in Table S1. (D and 
F) Increasing concentrations of SAP (PRM-151) (D) or ruxolitinib (F) were added to fibrocyte cultures 24 h after the initiation of cultures. After 7 d, the 
number of viable (morphologically intact and adherent to the bottom of the slide) fibrocytes/2.5 × 105 cells were counted independently by two individuals. 
Untreated cell cultures were used as a reference to calculate the percent viable fibrocytes. The mean ± SD of percent viable fibrocytes obtained from four 
(normal) or six (PMF) BM samples are depicted. Differences were calculated using two-way analysis of variance. The p-values reported are for variance by 
drug concentration. (E) A comparison of the EC50 of SAP between normal and PMF BM fibrocytes (P = 0.038; Mann-Whitney test). Unlike SAP in D, ruxolitinib 
did not affect fibrocyte differentiation in F. Four normal and six PMF BM samples were tested.
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Figure 6. BM analysis of untreated and SAP (PRM-151)–treated MPL-W515L mice. (A) H&E and reticulin staining images of femur and spleen 
sections from MPL-W515L–induced myelofibrosis mice. Images are representative of tissue sections from seven mice. The mean fibrosis grade was MF-3. 
Large numbers of immature myeloid cells and dense clusters of small to large megakaryocytes with aberrant nuclear cytoplasmic ratios and hyperchromatic 
9JEM
placebo (the vehicle of PRM-151) starting 2 wk after trans-
plantation (Fig. 9 A). At the same time, 10 nontransplanted, 
untreated NSG mice were monitored (control). All trans-
planted, placebo-treated NSG mice lost weight (Fig.  9  C), 
became sick and moribund, and were euthanized, whereas 
all SAP (PRM-151)–treated or control (nontransplanted or 
normal BM transplanted) mice were alive and healthy during 
this period (Fig. 9 D).
All transplanted, placebo-treated mice had leukocytosis, 
anemia, and thrombocytosis (Fig. 9 E), and on necropsy, they 
had marked splenomegaly, and their BM and spleens were 
heavily infiltrated with immature myeloid cells and atypical 
megakaryocytes. Extramedullary hematopoiesis was occa-
sionally detected in their lungs (not depicted), whereas their 
livers appeared morphologically intact, and none of the mice 
had blastic transformation. However, dilated sinusoids, intrasi-
nusoidal hematopoiesis, and BM and spleen fibrosis were de-
tected in all sections (Fig. 10, B and C). A granuloma was seen 
in one splenic section (Fig. 10 C).
On day 239 after transplantation when all placebo-treated 
mice had become sick and been euthanized, two SAP-treated 
mice from group A, two from group B, and two nontrans-
planted mice (control) were euthanized. None of these mice 
showed external signs of illness at the time of sacrifice. Their 
spleen sizes were similar to those of the nontransplanted age-
matched mice (Fig. 10 D). Mouse–human chimerism was de-
tected by FISH in all SAP (PRM-151)– and placebo-treated 
mice but not the nontransplanted controls (Fig. 10 A). Un-
like placebo-treated mice, in mice that started treatment at 
2 wk (group A), only mild focal BM and spleen fibrosis was 
detected. The BM megakaryocytes appeared normal, and 
although myeloid cells were detected in their spleens, the 
splenic architecture was largely preserved (Fig. 10 B, second 
panel from the right). Similarly, in mice that started treatment 
at 2 mo, BM and spleen sections showed clusters of hyper-
chromatic megakaryocytes and diffuse areas of mild reticu-
lin fibrosis (Fig. 10 B, group B). In contrast, tissue sections 
from the nontransplanted untreated mice showed a normal 
splenic architecture and normal spleen and BM morphology 
(Fig. 10 B, control). As expected, the number of fibrocytes in 
BM and spleen (CD45+/CD68+ and CD45+/procollagen I+ 
cells) tissues from the SAP (PRM-151)-treated mice was sig-
nificantly lower than the number in those of placebo-treated 
mice (Fig. 10 E). In addition, SAP (PRM-151)–treated mice 
had normal white blood cell (WBC) counts and hemoglobin 
levels, though their platelet counts remained high (Fig. 9 E). 
There were no obvious changes in BM cellularity or mega-
karyocyte counts after SAP (PRM-151) treatment. 8 mo after 
injection of BM cells, we discontinued treatment with SAP, 
and all mice died of PMF without transformation to acute 
leukemia (Fig.  10  F), indicating that continued treatment 
with SAP (PRM-151) was necessary to inhibit the develop-
ment of the myelofibrosis-like phenotype in xenograft mice.
DIS CUS SION
BM fibrosis in PMF is presumed to be caused by growth 
factors released from clonal megakaryocytes or platelets that 
stimulate MSCs to induce BM fibrosis (Groopman, 1980). 
Here, we demonstrate that clonal neoplastic fibrocytes, which 
are significantly expanded in patients with PMF, are func-
tionally distinct from normal fibrocytes (perhaps because of 
constitutive JAK2 signaling) and contribute to the formation 
of BM fibrosis. Furthermore, SAP (PRM-151) slowed the de-
velopment of fibrosis and significantly improved survival of 
NSG mice transplanted with PMF BM cells.
That fibrocytes play a direct role in the induction of BM 
fibrosis is not unprecedented. Ohishi et al. (2012) found an 
expanded population of CD45+ cells that produced type I col-
lagen (fibrocytes) in the BM of mice conditionally expressing 
active parathyroid hormone receptor, results that are reminis-
cent of our data obtained from the mouse MPL-W515L–in-
duced PMF model. In the parathyroid hormone receptor mice, 
the numbers of MSCs in BM from control mice and mice with 
hyperparathyroidism-induced BM fibrosis were similar. Similar 
to our findings, Arranz et al., 2014 found a reduced number of 
MSCs in BM specimens of JAK2-V617F–positive myelopro-
liferative neoplasm patients and mice expressing JAK2-V617F 
in the hematopoietic system (Tiedt et al., 2008). Consistent 
with our data, the reduction in MSCs was concomitant with 
the formation of BM fibrosis in mice, suggesting that other 
cells rather than MSCs are the major contributors to the for-
mation of BM fibrosis in myeloproliferative neoplasms.
and irregular nuclei in both the BM and spleen are shown. In both tissues, significant reticulin fibrosis was detected by reticulin staining. Bars: (H&E) 100 
µm; (reticulin) 50 µm. (B and C) BM (top) and spleen (bottom) sections from MPL-W515L–induced MF mice (B) and control mice (MPL-WT; C) stained for 
CD11 and procollagen I and CD68 and procollagen I. Unlike the WT (control) mice, BM and spleen cells from MPL-W515L mice stained positively for CD11/
procollagen I (yellow; top, bottom right) and CD68/procollagen I (yellow; bottom, bottom right). Results are representative of two MPL-W515L mice and two 
MPL-WT mice. Bars, 50 µm. (D) Quantitation of immunostained cells in BM and spleen sections. Images of random HPFs of four slides from four different 
mice were analyzed using an automated multispectral imaging microscope. Box and whisker plots of CD11b+, CD45+, CD68+, procollagen I+ (Procol-I), and 
dual-labeled cells (merge) per square millimeter are shown. Boxes show the median and interquartile range, and whiskers denote the minimum and maxi-
mum data points. ***, P < 0.001 (Student’s t test comparing MPL-WT and MPL-W515L [merge]). (E) BM and spleen sections from MPL-W515L mice treated 
with either placebo or SAP. Images are representative of tissue sections from seven placebo-treated mice and six SAP-treated mice. The mean fibrosis grade 
was MF-3 in placebo-treated mice, and SAP-treated mice ranged from MF-0 to MF-1. Both placebo- and SAP-treated sections showed hypercellularity, a 
high M:E ratio, and atypical megakaryocytes and blasts. However, placebo-treated mice had much more BM fibrosis than the SAP-treated mice, which hardly 
had any. Bars: (H&E) 100 µm; (reticulin) 50 µm. (F) Quantitation of immunostained cells in BM and spleen sections of placebo- and SAP (PRM-151)–treated 
MPL-W515L mice. Data are presented as in D. ****, P < 0.0001.
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To test our hypothesis that fibrocytes mediate the in-
duction of fibrosis in PMF, we transplanted NSG mice with 
PMF BM–derived low-density cells. Because low-density 
BM cells from patients with chronic myelogenous leuke-
mia have been shown to engraft NSG mice (Verstegen et al., 
1999), PMF-derived CD34+ cells have been shown to in-
duce acute myeloid leukemia but not PMF in NSG mice 
(Triviai et al., 2014), and CD34− cells have been shown to 
engraft NSG mice (Bhatia et al., 1998; Zanjani et al., 1998), 
we opted to inject mice with unfractionated low-density cells 
to avoid excluding any cellular population that may be im-
portant for engraftment or the establishment of human PMF 
in mice. As in human PMF BM and the BM and spleen of 
MPL-W515L mice, the fibrotic hematopoietic tissue of the 
xenograft mice was characterized by a massive expansion of 
clonal fibrocytes. Although low-density cells from normal 
BM also engrafted, few BM fibrocytes were detected, and the 
mice did not develop PMF.
In both PMF mouse models, we found increased num-
bers of atypical megakaryocytes, a defining pathological fea-
ture of PMF. Interestingly, TGF-β, which is highly expressed 
in megakaryocytes from patients with PMF (Martyré et al., 
1997), has been shown to play a role in fibrocyte differen-
tiation (Hong et al., 2007). Thus, megakaryocyte-derived 
cytokines may in fact promote fibrosis, but more likely by 
promoting differentiation of fibrocytes.
SAP has been shown to inhibit the differentiation of 
fibrocytes from monocytes and to reduce fibrosis in various 
organs (Haudek et al., 2006, 2008; Pilling et al., 2007; Castaño 
et al., 2009; Murray et al., 2011; Reilkoff et al., 2011). In ad-
dition, SAP promotes immunoregulatory macrophages that 
secrete IL-10, which is known to modulate fibrosis (Castaño 
Figure 7. Engraftment of human PMF BM–derived cells in NSG mice. (A) Representative flow cytometry plot of PB from NSG mice injected with 
normal human or PMF BM–derived low-density cells showing the presence of cells carrying the HLA-ABC antigen. PB cells were assessed 14 d after injection 
of BM cells and approximately every 2–4 wk thereafter to confirm the mouse–human chimerism. Approximately the same level of HLA-ABC–positive cells 
was detected throughout the animal’s life (Table S4). (B) Karyotype (Giemsa banding) analysis of BM cells obtained from NSG mice injected with PMF BM–
derived low-density cells. The arrow indicates the 20q deletion in the human cells. (C) FISH analysis of BM cells from xenograft mice using probes specific 
for 20q and 1q (internal control). DAPI nuclear staining is shown in blue. Both mouse and human cells are depicted. Bar, 10 µm. (D) Mouse spleens 3 mo 
after injection of PMF or normal BM low-density cells. Spleens from nontransplanted (NT) mice are shown for comparison. (E) H&E and reticulin staining 
of BM (femur) and spleen sections of mice injected with normal or PMF BM low-density cells. Notable features in PMF include atypical megakaryopoiesis 
anisocytosis, abnormal large nuclear/cytoplasmic ratio, hyperchromatic nuclei, and plump lobulation of the nuclei. Reticulin-stained BM sections from 
mice injected with PMF BM cells shows increased reticulin fibrosis. In contrast, in mice injected with normal BM cells, hematopoiesis is unaltered, splenic 
architecture is preserved, and no significant reticulin fiber deposition is observed. Images are representative of 10 mice injected with normal BM cells and 
10 injected with PMF BM cells. The fibrosis grade ranged from MF-2 to MF-3 in PMF BM–injected mice, and no fibrosis was seen in any of the normal BM–
injected mice. Bars: (H&E) 100 µm; (reticulin) 50 µm.
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et al., 2009; Cox et al., 2015). We found that patients with 
PMF had low plasma SAP and high plasma CRP levels com-
pared with healthy individuals, suggesting that the low SAP 
levels in PMF patients are less likely to be caused by reduced 
production than by increased consumption and clearance 
(Bottazzi et al., 2010).
Our finding that SAP (PRM-151) significantly pro-
longed the life of PMF xenograft mice and slowed the for-
mation of BM fibrosis provides compelling evidence that 
hematopoietic tissue fibrosis is induced by fibrocytes and 
suggests that SAP may inhibit or reverse BM fibrosis in pa-
tients with myelofibrosis. Indeed, the number of fibrocytes 
was markedly reduced in the BM and spleens of SAP-treated 
compared with placebo-treated mice. Furthermore, the total 
number of WBCs and CD45+ cells was also reduced in SAP-
treated mice, suggesting that neoplastic fibrocytes may directly 
or indirectly sustain the neoplastic clone or that SAP has an-
other yet undefined mechanism of action (Kleaveland et al., 
2014). Discontinuation of treatment, however, led to reestab-
lishment of PMF and eventual death of the transplanted mice.
Figure 8. Quantitation of clonal fibrocytes in xenograft mice. (A and B) Immunohistochemical staining of BM (top) and spleen (bottom) sections 
of mice injected with PMF BM–derived low-density cells (A) or normal human BM–derived low-density cells (B). Bars, 50 µm. (C) Quantitation of immu-
nostained cells in BM and spleen sections. Images of five random HPFs per slide were analyzed using an automated multispectral imaging microscope. 
Data represent analysis of five slides from five different animals. Box and whisker plots of CD45+, CD68+, procollagen I+ (Procol-I), and dual-labeled cells 
(Merge) per square millimeter are shown. Boxes represent the median and interquartile range, and whiskers denote the minimum and maximum data points. 
**, P < 0.01; ***, P < 0.001 (Student’s t test with Welch’s correction comparing normal and PMF [merge]). (D and E) Clonality assessment of fibrocytes from 
mice injected with PMF-derived BM cells. (D) Representative flow cytometry dot plot showing that 11% of cells flushed from the femurs of xenograft mice 
injected with BM low-density cells from a PMF patient with a 20q deletion coexpressed human CD45+/CD68+ antigens. (E) FISH image of fibrocytes cultured 
from BM cells harvested from the same xenograft mice shows the presence of the 20q deletion in the cultured fibrocytes. Bar, 10 µm.
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Samples and cell fractionation
We used diagnostic BM samples that were obtained before 
treatment from patients with PMF treated at the University 
of Texas MD Anderson Cancer Center during a 4-yr period. 
Institutional Review Board approval and written patient in-
formed consent were obtained. The clinical characteristics 
of the patients are presented in Table S1. Hematologically 
normal BM and peripheral blood (PB) samples were pur-
chased from STE MCE LL Technologies for comparison. BM 
and PB cells were fractionated using Ficoll Hypaque 1077 
(Sigma-Aldrich). After the buoyant low-density cells were 
aspirated, a red blood cell lysis buffer (QIA GEN) was added 
for 5 min, and the remaining granulocytes were harvested 
and washed in PBS (Invitrogen). CD14+ and CD14− cells 
were selected from the low-density cell fraction using Easy-
Sep magnetic microbeads (STE MCE LL Technologies) ac-
cording to the manufacturer’s instructions.
Fibrocyte cell culture assay
Low-density BM cells were cultured in conditions that 
promote differentiation of monocytes to fibrocytes (Pilling 
et al., 2003) as described previously (Pilling et al., 2009). 
In brief, CD14+ monocytes purified from low-density BM 
cells (purity >97%) were cultured with serum-free me-
dium (StemPro-34; Invitrogen) supplemented with 10 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Sig-
ma-Aldrich), 1× nonessential amino acids (Sigma-Aldrich), 
1 mM sodium pyruvate (Sigma-Aldrich), 2 mM glutamine 
(Invitrogen), 100 U/ml penicillin, 100 µg/ml streptomycin, 
and 1× ITS-3 (containing 10 µg/ml insulin, 5 µg/ml trans-
ferrin, 5 ng/ml sodium selenite, 0.5 mg/ml albumin, 5 µg/
ml oleic acid, and 5 µg/ml linoleic acid [Sigma-Aldrich]), 
either in flat-bottomed 96-well plates or in Lab-Tek mi-
croscope chamber slides (CC2 slides; Thermo Fisher Scien-
tific). Culture plates and slides were maintained at 37°C in 
humidified air supplemented with 5% CO2.
Figure 9. Characterization of xenograft 
mice treated with SAP. (A) SAP (PRM-151) 
treatment schedule. Mice were injected with 
10 mg/kg daily for the first 9 d and then twice 
per week thereafter. (B) Kaplan-Meier survival 
analysis of 10 mice treated with placebo and 
10 treated with SAP starting the day after in-
jection of PMF BM cells. (C) Plot showing mean 
± SEM change in the weight of nontrans-
planted (control), placebo-treated (placebo), 
and SAP-treated (group A and group B) PMF 
BM–transplanted mice. Weight was measured 
at six different time points. (D) Kaplan-Meier 
survival analysis of xenograft mice treated 
with placebo or SAP 2 wk (group A) or 2 mo 
(group B) after injection of PMF BM cells. Ar-
rows indicate times of treatment initiation. 
Placebo-treated mice were euthanized in ac-
cordance with our institutional protocol 79 (n 
= 1), 88 (n = 2), 103 (n = 5), 181 (n = 1), and 
205 (n = 1) d after transplantation. With 10 
mice per group and assuming a 10% survival 
rate for the placebo group and 90% for the 
treatment groups, we have 82% power with 
a type 1 error rate of 0.05% to test our hy-
pothesis that mice treated with SAP live sig-
nificantly longer than those treated with the 
placebo. (E) PB counts of control (n = 10), pla-
cebo-treated (n = 8), and SAP-treated (n = 4, 
2 in group A and 2 in group B) mice obtained 
before the placebo-treated mice were eutha-
nized. Black lines represent the median. Unlike 
placebo-treated mice, SAP (PRM-151)–treated 
mice did not have anemia, and the WBC counts 
were normalized. However, the platelet counts 
of SAP-treated mice remained high, similar to 
the placebo-treated mice.
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Figure 10. Characterization of xenograft mice treated with SAP either before or after the development of BM fibrosis. (A) FISH analysis of BM 
sections from normal, nontransplanted, untreated mice (left) or PMF BM–transplanted mice treated with SAP 2 wk after transplantation (group A) or 2 mo 
after transplantation (group B) using probes for human and mouse centromeres. Cells harboring human centromeres were detected in 10% of the analyzed 
slides. Bar, 10 µm. (B) Representative H&E and reticulin staining of femur and spleen sections from a nontransplanted normal, age-matched control mouse, 
a PMF BM–transplanted placebo-treated mouse, and a PMF BM–transplanted mouse treated with SAP (PRM-151) starting either 2 wk (group A) or 2 mo 
(group B) after transplantation. Bars: (H&E) 100 µm; (reticulin) 50 µm. (C) H&E staining of BM and spleen sections from transplanted, placebo-treated NSG 
mice showing numerous atypical megakaryocytes, some of which were present within the sinuses (left, white arrow), dilated sinusoids, intrasinusoidal 
hematopoiesis with evolving myelofibrosis (yellow arrow), and an increase in immature myeloid cells. (Right) The spleen section shows myeloid sarcoma 
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Cells were visualized using a phase-contrast microscope 
(ELWD 0.3; 10/0.25 objective lens; Nikon), photographed 
using a digital camera (D40; Nikon), and counted as previ-
ously described (Pilling et al., 2003; 2009). The number of 
fibrocytes generated in culture varied by patient sample but 
ranged from 200 to 400 cells.
MSC culture assay
BM cells from patients with PMF and healthy donors were 
cultured in conditions that support MSC proliferation. 
Low-density BM cells (106 cells/ml) were cultured in α-mod-
ified Eagle’s medium (Invitrogen) supplemented with 20% 
FCS (Invitrogen). The medium was replenished twice weekly. 
For further analysis, adherent MSCs were washed with PBS, 
pH 7.4, and removed after incubation with 0.25% trypsin 
(Sigma-Aldrich) for 5–7 min. Cultures were photographed 
and manually assessed at days 7, 14, and 21 as described for the 
cultured fibrocytes in the previous section.
Immunofluorescence
Paraffin-embedded 4-µm BM biopsy sections were oven 
dried for 1 h at 56°C, deparaffinized, rinsed three times in xy-
lene, and rehydrated using graded concentrations of ethanol 
(100%, 90%, 80%, and 70%), and the epitopes were retrieved 
with Diva decloaker buffer in a decloaking chamber using 
the Mach-3 system (Biocare Medical). Cells were cultured in 
8-well microscope chamber slides for 14 d, washed with PBS, 
and fixed in 4% formaldehyde. Slides were washed in PBS 
and incubated with primary antibodies at a predetermined 
concentration (Table S2) for 3 h at room temperature, and 
BM sections were incubated for 12 h with primary antibod-
ies in blocking buffer in a humidified chamber on a shaker 
at 4°C. Slides were then washed in PBS and incubated with 
Alexa Fluor–conjugated antibodies (Table S2; Invitrogen) for 
1 h at room temperature, washed in PBS, and counterstained 
with DAPI (Invitrogen). Antifade fluorescent mounting me-
dium (Dako) was added, and the coverslip was applied.
Images were captured using a 20×/0.9 objective lens 
mounted on a microscope (Exfo; ZEI SS) and recorded and 
processed using AxioVision software (ZEI SS). For quan-
titative analysis, images were analyzed using a Vectra 2 (I × 
81; Olympus) automated multispectral imaging microscope 
(PerkinElmer). High-power fields (HPFs; 40×) were man-
ually chosen, with at least 25 fields per sample. Data were 
analyzed using inForm software (PerkinElmer). Normal-
ization and background correction were performed using 
an unstained slide and a slide stained with the secondary 
antibody/DAPI to generate an analysis library. Randomly se-
lected HPFs from four different slides were analyzed for each 
BM sample. Samples from three patients and three controls 
were analyzed in each experiment.
Silver staining for reticulin fibers
The reticulin silver Chromaview advance testing kit (Rich-
ard-Allen Scientific) was used for staining BM-derived 
cultured fibrocytes and MSCs in accordance with the manu-
facturer’s instructions.
DNA extraction and quantitation of the JAK2 mutant  
T allele and CALR mutation
Granulocytes, low-density BM cells, cultured BM-derived 
fibrocytes, and MSCs from patients with PMF known to har-
bor either the JAK2 (n = 12) or CALR (n = 7) mutations 
were tested for the presence of these mutations. We also ex-
amined the mutation status of seven normal BM samples and 
five normal PB samples as a control. Fibrocytes and MSCs 
were cultured as described in the Fibrocyte cell culture assay 
and MSC culture assay sections. After 14 d in culture, the 
adherent fibrocytes or MSCs were washed three times with 
PBS, pH 7.4, to remove the nonadherent cells. Puregene 
DNA lysis buffer was then added directly to the adherent 
cells. Genomic DNA was extracted using Puregene DNA 
purification reagents (Gentra). Total genomic DNA was used 
for PCR amplification of JAK2 exon 14, and quantitative 
allele-specific suppressive PCR was performed as described 
previously (Quintás-Cardama et al., 2011). Insertions or de-
letions in the CALR gene were analyzed by PCR fragment 
analysis as previously described (Klampfl et al., 2013).
FISH
Slides of BM fibrocytes, MSCs, and mouse and human BM 
tissue were washed in PBS and dehydrated in ethanol, as de-
scribed for the BM biopsy specimens in the Immunofluores-
cence section, and treated with RNase for 1 h at 37°C. Slides 
with numerous blasts disrupting the splenic architecture (white arrow). Images are representative of tissue sections from 10 nontransplanted mice, 10 PMF 
BM–transplanted placebo-treated mice, and two SAP-treated mice from group A and two from group B. The BM fibrosis grade ranged as follows: nontrans-
planted, no fibrosis; placebo, MF-2 to MF-3; group A, no fibrosis; and group B, MF-0 to MF-1. Bar, 100 µm. (D) Spleens of SAP-treated mice from group A (A) 
and group B (B) and an age-matched nontransplanted (NT) mouse. Spleen weights were as follows: nontransplanted group, 0.09–0.105 g; placebo group, 
0.165–0.224 g with one spleen weighing 31.8 g; group A, 0.083–0.101 g; and group B, 0.092–0.112 g. (E) Quantitation of immunostained cells in BM and 
spleen sections. Images are of random HPFs of four different slides from four animals for the placebo group, two animals for group A, and two animals for 
group B analyzed using an automated multispectral imaging microscope. Box and whisker plots of CD45+, CD68+, procollagen I+ (Procol-I), and dual-labeled 
cells (Merge) per square millimeter are shown. Boxes represent the median and interquartile range, and whiskers denote the minimum and maximum data 
points. **, P < 0.01; ****, P < 0.0001 (Student’s t test with Welch’s correction comparing placebo vs. group A or group B [merge]). (F) Kaplan-Meier survival 
analysis of mice treated with placebo (n = 10) or SAP 2 wk (n = 10; group A, blue arrow) or 2 mo (n = 10; group B, green arrow) after injection of PMF BM 
cells showing survival after the discontinuation of SAP treatment (day 247; black arrow). 10 nontransplanted, untreated mice were used as a control group. 
All mice in both groups became sick and were sacrificed 311–470 d after injection of PMF BM cells.
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were then incubated with 2× saline-sodium citrate (SSC) 
buffer (0.3 M sodium chloride and 30 mM sodium citrate, 
pH 7.0) for 30 min, left overnight in 1 M sodium isothiocya-
nate, and rinsed with 2× SSC. Slides were treated with 4 mg/
ml pepsin (Vysis; Abbott Molecular) at 37°C, washed in 2× 
SSC at room temperature, dehydrated with 70% ethanol, and 
air dried. A mixture of probes (Abbott Molecular) detecting 
chromosomes 1p, 1q, or 20q, human centromeres, or mouse 
centromeres was denatured at 74°C for 5 min and applied to 
the cells. Slides were sealed with a coverslip and rubber ce-
ment (Thermo Fisher Scientific) and incubated overnight at 
37°C in a humidified atmosphere. The coverslips were then 
removed, and the slides were washed in 2× SSC at 45°C for 
30 min, counterstained with 1 µg/ml DAPI, and mounted 
with antifade mounting medium (Dako). Fluorescence-spe-
cific signals were visualized by fluorescence microscopy, and 
the images were captured at a magnification of 100 with a mi-
croscope (Eclipse 80i; Nikon) equipped with a Photometrics 
SenSys charged-coupled device camera (Roper Technologies). 
Images were analyzed using Metamorph software (Molecular 
Devices). The analysis was performed with coded BM sam-
ples in a core pathology laboratory at our institution, and the 
pathologist had no knowledge of the origin of the slides. A 
cell was considered positive for the chromosomal marker only 
in cases where the internal control probe was also visualized.
Clonogenic assays
Normal and PMF BM low-density cells were incubated in 
methylcellulose alone as previously described (Estrov et al., 
1987) or on top of a preestablished adherent layer of a similar 
number of normal and PMF BM–derived fibrocytes. For the 
adherent under layer, fibrocytes were cultured from normal or 
PMF BM low-density cells as described previously (Pilling et 
al., 2003, 2009). The adherent fibrocytes were washed three 
times with PBS, pH 7.4, to remove the nonadherent cells, and 
then the BM low-density cells were placed on top of them. 
In brief, 2 × 105 low-density cells were mixed in 0.8% meth-
ylcellulose in IMDM supplemented with 10% FCS, 1.0 U/
ml human erythropoietin (Amgen), 50 ng/ml human stem 
cell factor (Amgen), 50 ng/ml human GM-CSF, or 10 ng/
ml thrombopoietin. 500 ml of the mix was cultured either 
alone or on top of the adherent fibrocytes and incubated at 
37°C in a humidified atmosphere of 5% CO2 in air. All cul-
tures were evaluated after 14 d for the presence of eryth-
roid burst-forming units (BFU-Es) defined as an aggregate 
of >500 hemoglobinized cells or ≥3 erythroid subcolonies, 
CFU granulocyte–macrophages (CFU-GMs) defined as a 
cluster of >50 granulocyte and/or monocyte/macrophage 
cells, or CFU megakaryocytes (CFU-Megs) defined as a clus-
ter of >10 large translucent CD41+ cells.
To test whether direct contact between the fibrocytes 
and BM cells affected proliferation capacity, fibrocyte cultures 
were overlaid with 0.5% low gelling temperature agar (Sig-
ma-Aldrich) in IMDM. After setting, the agarose was overlaid 
with the normal clonogenic culture media mix, and CFUs 
were counted as described in the previous paragraph. All ex-
periments were performed in duplicate.
Measurement of gene expression by quantitative RT-PCR
Cultured BM-derived fibrocytes from 23 patients with PMF 
and 9 normal donors were examined. Fibrocytes were cultured 
and washed as described in the previous section. Total RNA 
was extracted from cultured fibrocytes by adding TRIzol re-
agent (Invitrogen) directly to the adherent cells. The RNA con-
centration was determined by NanoDrop (ND1000; Thermo 
Fisher Scientific), and 1 µg of total RNA was used to perform 
RT-PCR (SuperScript First-Strand; Invitrogen). Quantitative 
gene expression analysis for several target genes (Table S3) was 
conducted using the TaqMan expression assay kit (Applied Bio-
systems) or SYBR green on an ABI 7900HT FAST platform 
(Applied Biosystems). The Δ cycle threshold (ΔCt) value was 
calculated by subtracting the Ct value of a control gene (hGAP 
DH) from that of the target gene, and the expression level for 
each gene was calculated as follows: expression = 2−(ΔCt).
Measurement of secreted cytokines/chemokines
Fibrocytes were cultured from BM mononuclear cells as de-
scribed in the MSC culture assay and Fibrocyte cell culture 
assay sections. After 7 d, the supernatant was removed, the 
adherent cells were washed three times, and fresh fibrocyte 
media was added. After 10 d, the supernatants were collected 
for cytokine measurements. Bio-Plex prohuman inflamma-
tion 1 (37 Plex) and prohuman chemokine (40 Plex) panel 
assays (Bio-Rad Laboratories) were used for simultaneous 
quantitation of cytokines and chemokines according to the 
manufacturer’s instructions. The samples were analyzed using 
the Bio-Plex system and Bio-Plex Manager software with 5PL 
curve fitting (Bio-Rad Laboratories). The reader was set to 
read a minimum of 200 beads, and the results were expressed 
as median fluorescence intensity. Measurement of secreted 
TGF-β1 and TGF-β2 was performed using the Quantikine 
enzyme-linked immunosorbent assay (R&D Systems).
Treatment of fibrocytes with recombinant human SAP 
(PRM-151) and ruxolitinib
Cultures of normal or PMF BM–derived fibrocytes were ex-
posed to increasing concentrations of recombinant human SAP 
(EMD Millipore) or ruxolitinib 24 h after initiation of the cul-
tures. The JAK1/JAK2 inhibitor ruxolitinib (Chemie Tek) was 
dissolved in dimethyl sulfoxide (stock solution of 5 mM) and 
further diluted in the culture medium. After 7 d, viable (i.e., at-
tached to the slides and morphologically intact) fibrocytes were 
counted by two separate individuals. Data were normalized to 
the number of fibrocytes in the control (untreated) culture. The 
half-maximal effective concentration (EC50) for SAP and ruxoli-
tinib was calculated based on the percentage of viable fibrocytes.
Measurement of SAP, CRP, and albumin
Because SAP has been shown to inhibit fibrocyte differentia-
tion (Pilling et al., 2003), the levels of SAP, CRP, and albumin 
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were measured in 10 plasma samples from healthy donors and 
39 plasma samples from patients with PMF using multiplexed 
immunoassays (Rules-Based Medicine, Inc.), as previously 
described (Verstovsek et al., 2010).
BM analysis of the mouse model of MPL-
W515L–induced myelofibrosis
These animal studies were performed at the Memorial Sloan 
Kettering Cancer Center under an animal protocol approved 
by the Memorial Sloan Kettering Instructional Animal Care 
and Utilization Committee. Female mice transplanted with 
BM cells expressing a mutation in the thrombopoietin recep-
tor, MPL-W515L, developed a myelofibrosis-like phenotype 
characterized by thrombocytosis, splenomegaly, and reticulin 
fibrosis (Pikman et al., 2006). The MPL-W515L mice were 
generated as reported previously (Pikman et al., 2006). In 
brief, BM cells harvested from Balb/C mice were cultured 
in the presence of stem cell factor for 24 h and then infected 
with MPL-W515L–containing retrovirus. The infected cells 
were then injected into the tail veins of lethally irradiated 
Balb/C mice. To determine whether there is an increase in 
the number of fibrocytes in these mice, similar to what is 
seen in human PMF, we calculated the number of fibrocytes 
in BM and spleen samples from the MPL-W515L–trans-
planted mice using immunohistochemical analysis and HPF 
image analysis as described in the last paragraph of the Im-
munofluorescence section.
Xenograft mouse model
All animal studies were performed at the MD Anderson Can-
cer Center under an animal protocol approved by the MD 
Anderson Cancer Center Instructional Animal Care and Uti-
lization Committee. To establish the xenograft mouse model, 
PMF BM–derived low-density cells (106 suspended in 100 µl 
IMDM) were injected into the tail vein of ten 4–6-wk-old 
female NSG mice homozygous for Prkdcscid and IL-2Rgtm1Wjl 
(The Jackson Laboratory). As a control, 10 mice were also 
injected with normal BM low-density cells, and 10 mice were 
injected with IMDM. Engraftment of human cells was as-
sessed 2 wk after injection and once a month thereafter by 
flow cytometry of PB cells using FITC-labeled anti–HLA-
ABC antibodies (BD) and by RT-PCR to measure the JAK2 
allele burden. We obtained the same level of engraftment in 
lethally irradiated and unirradiated mice. Therefore, to cir-
cumvent any radiation-induced abnormalities, we performed 
all transplant experiments in unirradiated mice.
Assessment of SAP (PRM-151) treatment
In our initial xenograft mouse model experiments, we used 
10 mice per group, and all mice in the placebo group died, 
whereas none in the SAP treatment group died. If we assume 
a survival rate of 10% for mice in the placebo group and 90% 
for those in the treatment groups, using 10 mice per group 
gives us a power of 82% with a type I error rate of 0.05%.
NSG mice transplanted with PMF BM–derived cells 
were randomized into four groups of 10 mice as follows: (1) 
injected intravenously with IMDM but no BM cells, (2) trans-
planted with PMF BM cells and treated with placebo, (3) trans-
planted and treated with 10 mg/kg recombinant human SAP 
(PRM-151; Promedior, Inc.) starting 2 wk after transplantation, 
and (4) transplanted and treated with 10 mg/kg SAP starting 2 
mo after transplantation. The treated mice were given PRM-
151 intraperitoneally daily for 9 d and on two consecutive days 
weekly thereafter. This treatment schedule was used to mimic 
a human dosing schedule of days 1, 3, and 5 and then once a 
week, based on the knowledge that the half-life of PRM-151 
in mice is much shorter than that in humans (t1/2 = 8 vs. 30 h, 
respectively). Animals were selected at random by cage number 
for each treatment group before the injection of BM cells.
We also tested the effects of SAP in MPL-W515L mice. 
SAP treatment was started the day after induction following 
the treatment schedule described above (Fig. 9 A).The mice 
were euthanized in accordance with the experimental pro-
tocol when they became moribund, were unable to obtain 
food or water, or if they lost ≥20% of their body weight. 
Immediately after euthanasia, mouse femurs were removed 
and flushed with IMDM to extract BM cells for use in quan-
titative PCR and FISH analyses as described in the sections 
describing FISH and quantitation of gene mutations.
Cytogenetic analysis
Immediately after euthanasia, mouse femurs were removed and 
flushed with IMDM, and the flushed BM cells were washed 
twice and cultured in 20% FBS/IMDM supplemented with 
100 U/ml penicillin and 100 µg/ml streptomycin for 4 h at 
37°C. The cultured cells were incubated with 0.075 M KCl at 
room temperature for 20 min, after which 3 ml of a 3:1 meth-
anol/acetic acid (vol/vol) was added. Cells were then washed 
three times and dropped onto a wet glass slide and air dried. 
Slides were optimally aged (3 d at 65°C), and then Giemsa 
was banded following routine laboratory techniques. G-band 
metaphase spreads from each sample were photographed 
using a microscope (80i; Nikon) equipped with karyotyping 
software from Applied Spectral Imaging Inc.
Morphological analysis
Morphological analysis of mouse tissue was conducted after 
staining tissues with hematoxylin and eosin (H&E) using 
standard methods. For the assessment of reticulin fibrosis, tis-
sues were silver stained using a standard method. An expert 
pathologist (C.E. Bueso-Ramos) performed the morpholog-
ical analysis and interpretation. All histological and morpho-
logical comparisons of BM histology, fibrocyte morphology, 
and silver staining were assessed in a blinded fashion by a he-
matopathologist who was not aware of the project, its details, 
or the significance of the findings on the slides he analyzed. 
The degree of BM fibrosis was assessed according to the Eu-
ropean consensus criteria (Thiele et al., 2005).
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Statistical analysis
Groups were compared using two-sided Student’s t tests 
with Welch’s correction in cases where the variances were 
not equal. Differential gene expression or cytokine levels 
were visualized as heat maps using the Java TreeView ex-
tensible visualization of microarray data. The Kaplan-Meier 
method was used to analyze overall survival of mice. The 
log-rank test was used to compare survival. Linear correla-
tions were measured with the Pearson correlation coefficient. 
All statistical analyses were performed using Prism software 
(v6; GraphPad Software).
Online supplemental material
Table S1 shows baseline characteristics of the patients. Table S2 
shows antibodies and FISH probes used in immunofluorescent 
analysis. Table S3 shows target genes and primers used in 
RT-PCR. Table S4 shows the percentage of human HLA-
ABC+ cells in xenograft mice over their lifetime. Online 
supplemental material is available at http ://www .jem .org /
cgi /content /full /jem .20160283 /DC1.
ACK NOW LED GME NTS
This research was performed in part in the Flow Cytometry and Cellular Imaging and 
Molecular Cytogenetics Core Facility, Center for Genetics and Genomics, which is 
supported in part by the MD Anderson Cancer Center support grant CA016672. The 
authors thank the family of Hanns A. Pielenz for their generous donation support-
ing this research.
D. Pilling has equity in Promedior, Inc. The authors declare no additional com-
peting financial interests.
 Author contributions: S. Verstovsek directed the project, obtained patient sam-
ples, and analyzed data. T. Manshouri designed and carried out experiments, analyzed 
data, and wrote the manuscript. D. Pilling, L. Knez, S.M. Post, C.E. Bueso-Ramos, E.L. 
Spaeth, D.M. Harris, and C.J. Creighton carried out experiments and analyzed data. 
K.J. Newberry analyzed the data and wrote the manuscript. H.M. Kantarjian provided 
patient samples and analyzed the clinical data. R.L. Levine provided tissue from MPL-
W515L mice and reviewed the manuscript. C.J. Creighton performed statistical anal-
yses. Z. Estrov designed and directed the project, analyzed data, and wrote the 
manuscript. All authors reviewed the final manuscript. 
Submitted: 22 February 2016
Accepted: 22 June 2016
REFERENCES
Abe, R., S.C. Donnelly, T. Peng, R. Bucala, and C.N. Metz. 2001. Peripheral 
blood fibrocytes: differentiation pathway and migration to wound sites. 
J. Immunol. 166:7556–7562. http ://dx .doi .org /10 .4049 /jimmunol .166 
.12 .7556
Arranz, L., A. Sánchez-Aguilera, D. Martín-Pérez, J. Isern, X. Langa, A. 
Tzankov, P. Lundberg, S. Muntión, Y.S. Tzeng, D.M. Lai, et al. 2014. 
Neuropathy of haematopoietic stem cell niche is essential for myelopro-
liferative neoplasms. Nature. 512:78–81.
Bhatia, M., D. Bonnet, B. Murdoch, O.I. Gan, and J.E. Dick. 1998. A newly 
discovered class of human hematopoietic cells with SCID-repopulating 
activity. Nat. Med. 4:1038–1045. http ://dx .doi .org /10 .1038 /2023
Bottazzi, B., A. Doni, C. Garlanda, and A. Mantovani. 2010. An integrated 
view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. 
Immunol. 28:157–183. http ://dx .doi .org /10 .1146 /annurev -immunol 
-030409 -101305
Bucala, R., L.A. Spiegel, J. Chesney, M. Hogan, and A. Cerami. 1994. 
Circulating fibrocytes define a new leukocyte subpopulation that medi-
ates tissue repair. Mol. Med. 1:71–81.
Castaño, A.P., S.L. Lin, T. Surowy, B.T. Nowlin, S.A. Turlapati, T. Patel, A. 
Singh, S. Li, M.L. Lupher Jr., and J.S. Duffield. 2009. Serum amyloid 
P inhibits fibrosis through FcγR-dependent monocyte-macrophage 
regulation in vivo. Sci. Transl. Med. 1:5ra13. http ://dx .doi .org /10 .1126 
/scitranslmed .3000111
Castro-Malaspina, H., R.E. Gay, S.C. Jhanwar, J.A. Hamilton, D.R. Chiarieri, 
P.A. Meyers, S. Gay, and M.A. Moore. 1982. Characteristics of bone mar-
row fibroblast colony-forming cells (CFU-F) and their progeny in pa-
tients with myeloproliferative disorders. Blood. 59:1046–1054.
Cox, N., D. Pilling, and R.H. Gomer. 2015. DC-SIGN activation mediates 
the differential effects of SAP and CRP on the innate immune system 
and inhibits fibrosis in mice. Proc. Natl. Acad. Sci. USA. 112:8385–8390. 
http ://dx .doi .org /10 .1073 /pnas .1500956112
Estrov, Z., A. Tawa, X.H. Wang, I.D. Dubé, H. Sulh, A. Cohen, E.W. Gelfand, 
and M.H. Freedman. 1987. In vitro and in vivo effects of deferoxamine 
in neonatal acute leukemia. Blood. 69:757–761.
Greenberg, B.R., L. Woo, I.C. Veomett, C.M. Payne, and F.R. Ahmann. 1987. 
Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic 
myelofibrosis. Br. J. Haematol. 66:487–490. http ://dx .doi .org /10 .1111 /j 
.1365 -2141 .1987 .tb01332 .x
Groopman, J.E. 1980. The pathogenesis of myelofibrosis in myeloproliferative 
disorders. Ann. Intern. Med. 92:857–858. http ://dx .doi .org /10 .7326 
/0003 -4819 -92 -6 -857
Harrison, C., J.J. Kiladjian, H.K. Al-Ali, H. Gisslinger, R. Waltzman, V. 
Stalbovskaya, M. McQuitty, D.S. Hunter, R. Levy, L. Knoops, et al. 
2012. JAK inhibition with ruxolitinib versus best available therapy for 
myelofibrosis. N. Engl. J. Med. 366:787–798. http ://dx .doi .org /10 .1056 
/NEJMoa1110556
Haudek, S.B., Y. Xia, P. Huebener, J.M. Lee, S. Carlson, J.R. Crawford, D. 
Pilling, R.H. Gomer, J. Trial, N.G. Frangogiannis, and M.L. Entman. 
2006. Bone marrow-derived fibroblast precursors mediate ischemic 
cardiomyopathy in mice. Proc. Natl. Acad. Sci. USA. 103:18284–18289. 
http ://dx .doi .org /10 .1073 /pnas .0608799103
Haudek, S.B., J. Trial, Y. Xia, D. Gupta, D. Pilling, and M.L. Entman. 2008. 
Fc receptor engagement mediates differentiation of cardiac fibroblast 
precursor cells. Proc. Natl. Acad. Sci. USA. 105:10179–10184. http ://dx 
.doi .org /10 .1073 /pnas .0804910105
Hong, K.M., J.A. Belperio, M.P. Keane, M.D. Burdick, and R.M. Strieter. 
2007. Differentiation of human circulating fibrocytes as mediated by 
transforming growth factor-β and peroxisome proliferator-activated 
receptor γ. J. Biol. Chem. 282:22910–22920. http ://dx .doi .org /10 .1074 
/jbc .M703597200
Hutchinson, W.L., E. Hohenester, and M.B. Pepys. 2000. Human serum am-
yloid P component is a single uncomplexed pentamer in whole serum. 
Mol. Med. 6:482–493.
International Agency for Research on Cancer and World Health Organization. 
Swerdlow, S.H., E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. 
Thiele, and J.W. Vardiman, editors. 2008. WHO classification of tumours 
of haematopoietic and lymphoid tissues. World Health Organization 
Press, Lyon, France. 439 pp.
Jacobson, R.J., A. Salo, and P.J. Fialkow. 1978. Agnogenic myeloid metaplasia: 
a clonal proliferation of hematopoietic stem cells with secondary myelo-
fibrosis. Blood. 51:189–194.
Keeley, E.C., B. Mehrad, and R.M. Strieter. 2011. The role of fibrocytes in 
fibrotic diseases of the lungs and heart. Fibrogenesis Tissue Repair. 4:2. http 
://dx .doi .org /10 .1186 /1755 -1536 -4 -2
Kisseleva, T., H. Uchinami, N. Feirt, O. Quintana-Bustamante, J.C. Segovia, 
R.F. Schwabe, and D.A. Brenner. 2006. Bone marrow-derived fibrocytes 
Fibrocytes induce bone marrow fibrosis in PMF | Verstovsek et al.18
participate in pathogenesis of liver fibrosis. J. Hepatol. 45:429–438. http 
://dx .doi .org /10 .1016 /j .jhep .2006 .04 .014
Klampfl, T., H. Gisslinger, A.S. Harutyunyan, H. Nivarthi, E. Rumi, J.D. 
Milosevic, N.C.C. Them, T. Berg, B. Gisslinger, D. Pietra, et al. 2013. 
Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. 
J. Med. 369:2379–2390. http ://dx .doi .org /10 .1056 /NEJMoa1311347
Kleaveland, K.R., B.B. Moore, and K.K. Kim. 2014. Paracrine functions of 
fibrocytes to promote lung fibrosis. Expert Rev. Respir. Med. 8:163–172. 
http ://dx .doi .org /10 .1586 /17476348 .2014 .862154
Maharjan, A.S., D. Pilling, and R.H. Gomer. 2011. High and low molecular 
weight hyaluronic acid differentially regulate human fibrocyte 
differentiation. PLoS One. 6:e26078. http ://dx .doi .org /10 .1371 /journal 
.pone .0026078
Martyré, M.C., M.C. Le Bousse-Kerdiles, N. Romquin, S. Chevillard, V. 
Praloran, J.L. Demory, and B. Dupriez. 1997. Elevated levels of basic 
fibroblast growth factor in megakaryocytes and platelets from patients 
with idiopathic myelofibrosis. Br. J. Haematol. 97:441–448. http ://dx .doi 
.org /10 .1046 /j .1365 -2141 .1997 .292671 .x
Mehrad, B., and R.M. Strieter. 2012. Fibrocytes and the pathogenesis of 
diffuse parenchymal lung disease. Fibrogenesis Tissue Repair. 5:S22. http ://
dx .doi .org /10 .1186 /1755 -1536 -5 -S1 -S22
Murray, L.A., Q. Chen, M.S. Kramer, D.P. Hesson, R.L. Argentieri, X. Peng, 
M. Gulati, R.J. Homer, T. Russell, N. van Rooijen, et al. 2011. TGF-beta 
driven lung fibrosis is macrophage dependent and blocked by Serum 
amyloid P. Int. J. Biochem. Cell Biol. 43:154–162. http ://dx .doi .org /10 
.1016 /j .biocel .2010 .10 .013
Nowell, P.C., and J.B. Finan. 1978. Cytogenetics of acute and chronic myelo-
fibrosis. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 29:45–50.
Ohishi, M., W. Ono, N. Ono, R. Khatri, M. Marzia, E.K. Baker, S.H. Root, T.L. 
Wilson, Y. Iwamoto, H.M. Kronenberg, et al. 2012. A novel population of 
cells expressing both hematopoietic and mesenchymal markers is present 
in the normal adult bone marrow and is augmented in a murine model 
of marrow fibrosis. Am. J. Pathol. 180:811–818. http ://dx .doi .org /10 
.1016 /j .ajpath .2011 .10 .028
Pikman, Y., B.H. Lee, T. Mercher, E. McDowell, B.L. Ebert, M. Gozo, A. 
Cuker, G. Wernig, S. Moore, I. Galinsky, et al. 2006. MPLW515L is a novel 
somatic activating mutation in myelofibrosis with myeloid metaplasia. 
PLoS Med. 3:e270. http ://dx .doi .org /10 .1371 /journal .pmed .0030270
Pilling, D., C.D. Buckley, M. Salmon, and R.H. Gomer. 2003. Inhibition of 
fibrocyte differentiation by serum amyloid P. J. Immunol. 171:5537–5546. 
http ://dx .doi .org /10 .4049 /jimmunol .171 .10 .5537
Pilling, D., D. Roife, M. Wang, S.D. Ronkainen, J.R. Crawford, E.L. Travis, 
and R.H. Gomer. 2007. Reduction of bleomycin-induced pulmonary 
fibrosis by serum amyloid P. J. Immunol. 179:4035–4044. http ://dx .doi 
.org /10 .4049 /jimmunol .179 .6 .4035
Pilling, D., T. Fan, D. Huang, B. Kaul, and R.H. Gomer. 2009. Identification of 
markers that distinguish monocyte-derived fibrocytes from monocytes, 
macrophages, and fibroblasts. PLoS One. 4:e7475. http ://dx .doi .org /10 
.1371 /journal .pone .0007475
Quintás-Cardama, A., T. Manshouri, Z. Estrov, D. Harris, Y. Zhang, A. Gaikwad, 
H.M. Kantarjian, and S. Verstovsek. 2011. Preclinical characterization 
of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest. New Drugs. 
29:818–826. http ://dx .doi .org /10 .1007 /s10637 -010 -9429 -z
Rampal, R., F. Al-Shahrour, O. Abdel-Wahab, J.P. Patel, J.P. Brunel, C.H. 
Mermel, A.J. Bass, J. Pretz, J. Ahn, T. Hricik, et al. 2014. Integrated genomic 
analysis illustrates the central role of JAK-STAT pathway activation in 
myeloproliferative neoplasm pathogenesis. Blood. 123:e123–e133. http 
://dx .doi .org /10 .1182 /blood -2014 -02 -554634
Reich, B., K. Schmidbauer, M. Rodriguez Gomez, F. Johannes Hermann, 
N. Göbel, H. Brühl, I. Ketelsen, Y. Talke, and M. Mack. 2013. Fibrocytes 
develop outside the kidney but contribute to renal fibrosis in a mouse 
model. Kidney Int. 84:78–89. http ://dx .doi .org /10 .1038 /ki .2013 .84
Reilkoff, R.A., R. Bucala, and E.L. Herzog. 2011. Fibrocytes: emerging 
effector cells in chronic inflammation. Nat. Rev. Immunol. 11:427–435. 
http ://dx .doi .org /10 .1038 /nri2990
Steel, D.M., and A.S. Whitehead. 1994. The major acute phase reactants: 
C-reactive protein, serum amyloid P component and serum amyloid 
A protein. Immunol. Today. 15:81–88. http ://dx .doi .org /10 .1016 /0167 
-5699(94)90138 -4
Thiele, J., and H.M. Kvasnicka. 2006. Grade of bone marrow fibrosis is 
associated with relevant hematological findings-a clinicopathological 
study on 865 patients with chronic idiopathic myelofibrosis. Ann. 
Hematol. 85:226–232. http ://dx .doi .org /10 .1007 /s00277 -005 -0042 -8
Thiele, J., H.M. Kvasnicka, F. Facchetti, V. Franco, J. van der Walt, and A. Orazi. 
2005. European consensus on grading bone marrow fibrosis and assess-
ment of cellularity. Haematologica. 90:1128–1132.
Tiedt, R., H. Hao-Shen, M.A. Sobas, R. Looser, S. Dirnhofer, J. Schwaller, 
and R.C. Skoda. 2008. Ratio of mutant JAK2-V617F to wild-type Jak2 
determines the MPD phenotypes in transgenic mice. Blood. 111:3931–
3940. http ://dx .doi .org /10 .1182 /blood -2007 -08 -107748
Triviai, I., M. Ziegler, U. Bergholz, A.J. Oler, T. Stübig, V. Prassolov, B. Fehse, 
C.A. Kozak, N. Kröger, and C. Stocking. 2014. Endogenous retrovirus 
induces leukemia in a xenograft mouse model for primary myelofibrosis. 
Proc. Natl. Acad. Sci. USA. 111:8595–8600. http ://dx .doi .org /10 .1073 /
pnas .1401215111
van Dop, W.A., J. Heijmans, N.V. Büller, S.A. Snoek, S.L. Rosekrans, E.A. 
Wassenberg, M.A. van den Bergh Weerman, B. Lanske, A.R. Clarke, D.J. 
Winton, et al. 2010. Loss of Indian Hedgehog activates multiple aspects 
of a wound healing response in the mouse intestine. Gastroenterology. 
139:1665–1676.e10. http ://dx .doi .org /10 .1053 /j .gastro .2010 .07 .045
Vener, C., N.S. Fracchiolla, U. Gianelli, R. Calori, F. Radaelli, A. Iurlo, S. 
Caberlon, G. Gerli, L. Boiocchi, and G.L. Deliliers. 2008. Prognostic 
implications of the European consensus for grading of bone marrow 
fibrosis in chronic idiopathic myelofibrosis. Blood. 111:1862–1865. http 
://dx .doi .org /10 .1182 /blood -2007 -09 -112953
Verstegen, M.M., J.J. Cornelissen, W. Terpstra, G. Wagemaker, and A.W. 
Wognum. 1999. Multilineage outgrowth of both malignant and normal 
hemopoietic progenitor cells from individual chronic myeloid leukemia 
patients in immunodeficient mice. Leukemia. 13:618–628. http ://dx .doi 
.org /10 .1038 /sj .leu .2401366
Verstovsek, S., H. Kantarjian, R.A. Mesa, A.D. Pardanani, J. Cortes-Franco, 
D.A. Thomas, Z. Estrov, J.S. Fridman, E.C. Bradley, S. Erickson-Viitanen, 
et al. 2010. Safety and efficacy of INCB018424, a JAK1 and JAK2 
inhibitor, in myelofibrosis. N. Engl. J. Med. 363:1117–1127. http ://dx 
.doi .org /10 .1056 /NEJMoa1002028
Verstovsek, S., R.A. Mesa, J. Gotlib, R.S. Levy, V. Gupta, J.F. DiPersio, J.V. 
Catalano, M. Deininger, C. Miller, R.T. Silver, et al. 2012. A double-
blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. 
Med. 366:799–807. http ://dx .doi .org /10 .1056 /NEJMoa1110557
Wang, J.C., H.D. Lang, S. Lichter, M. Weinstein, and P. Benn. 1992. 
Cytogenetic studies of bone marrow fibroblasts cultured from patients 
with myelofibrosis and myeloid metaplasia. Br. J. Haematol. 80:184–188. 
http ://dx .doi .org /10 .1111 /j .1365 -2141 .1992 .tb08898 .x
Yang, L., P.G. Scott, J. Giuffre, H.A. Shankowsky, A. Ghahary, and E.E. Tredget. 
2002. Peripheral blood fibrocytes from burn patients: identification and 
quantification of fibrocytes in adherent cells cultured from peripheral 
blood mononuclear cells. Lab. Invest. 82:1183–1192. http ://dx .doi .org 
/10 .1097 /01 .LAB .0000027841 .50269 .61
Zanjani, E.D., G. Almeida-Porada, A.G. Livingston, A.W. Flake, and M. 
Ogawa. 1998. Human bone marrow CD34- cells engraft in vivo and 
undergo multilineage expression that includes giving rise to CD34+ 
cells. Exp. Hematol. 26:353–360.
Zhang, H., I. Maric, M.J. DiPrima, J. Khan, R.J. Orentas, R.N. Kaplan, 
and C.L. Mackall. 2013. Fibrocytes represent a novel MDSC subset 
circulating in patients with metastatic cancer. Blood. 122:1105–1113. 
http ://dx .doi .org /10 .1182 /blood -2012 -08 -449413
